Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

ANKRD22 is involved in the progression of prostate cancer.

Qiu Y, Yang S, Pan T, Yu L, Liu J, Zhu Y, Wang H.

Oncol Lett. 2019 Oct;18(4):4106-4113. doi: 10.3892/ol.2019.10738. Epub 2019 Aug 9.

2.

Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.

Peng S, Du T, Wu W, Chen X, Lai Y, Zhu D, Wang Q, Ma X, Lin C, Li Z, Guo Z, Huang H.

Urol Oncol. 2018 Aug;36(8):366.e1-366.e9. doi: 10.1016/j.urolonc.2018.05.021. Epub 2018 Jun 19.

PMID:
29903461
3.

ANKRD22 promotes progression of non-small cell lung cancer through transcriptional up-regulation of E2F1.

Yin J, Fu W, Dai L, Jiang Z, Liao H, Chen W, Pan L, Zhao J.

Sci Rep. 2017 Jun 30;7(1):4430. doi: 10.1038/s41598-017-04818-y.

4.

Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report.

Pins MR, Fiadjoe JE, Korley F, Wong M, Rademaker AW, Jovanovic B, Yoo TK, Kozlowski JM, Raji A, Yang XJ, Lee C.

Prostate Cancer Prostatic Dis. 2004;7(3):243-8.

5.

High levels of glioma tumor suppressor candidate region gene 1 predicts a poor prognosis for prostate cancer.

Ma X, Du T, Zhu D, Chen X, Lai Y, Wu W, Wang Q, Lin C, Li Z, Liu L, Huang H.

Oncol Lett. 2018 Nov;16(5):6749-6755. doi: 10.3892/ol.2018.9490. Epub 2018 Sep 24.

6.

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.

Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

PMID:
30843003
7.

Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival.

Bostwick DG, Qian J, Pacelli A, Zincke H, Blute M, Bergstralh EJ, Slezak JM, Cheng L.

J Urol. 2002 Sep;168(3):1204-11.

PMID:
12187268
8.

Serial analysis of resected prostate cancer suggests up-regulation of type 1 IGF receptor with disease progression.

Turney BW, Turner GD, Brewster SF, Macaulay VM.

BJU Int. 2011 May;107(9):1488-99. doi: 10.1111/j.1464-410X.2010.09556.x. Epub 2010 Sep 14.

9.

High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.

Xie JJ, Zhuo YJ, Zheng Y, Mo RJ, Liu ZZ, Li BW, Cai ZD, Zhu XJ, Liang YX, He HC, Zhong WD.

Int Urol Nephrol. 2017 May;49(5):817-823. doi: 10.1007/s11255-017-1545-7. Epub 2017 Feb 17.

PMID:
28213802
10.

Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.

Geybels MS, Wright JL, Bibikova M, Klotzle B, Fan JB, Zhao S, Feng Z, Ostrander EA, Lin DW, Nelson PS, Stanford JL.

Clin Epigenetics. 2016 Sep 15;8:97. doi: 10.1186/s13148-016-0260-z. eCollection 2016.

11.

Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence.

Velasco A, Hewitt SM, Albert PS, Hossein M, Rosenberg H, Martinez C, Sagalowsky AI, McConnell JD, Marston W, Leach FS.

Cancer. 2002 Feb 1;94(3):690-9. Erratum in: Cancer 2002 May 15;94(10):2800.

12.

MUC1 Expression in Prostate Carcinoma: Correlation with Grade and Stage.

Kirschenbaum A, Itzkowitz SH, Wang JP, Yao S, Eliashvili M, Levine AC.

Mol Urol. 1999;3(3):163-168.

PMID:
10851319
13.
14.

PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.

Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H.

Mayo Clin Proc. 2001 Jun;76(6):576-81.

PMID:
11393495
15.

SAMD5 mRNA was overexpressed in prostate cancer and can predict biochemical recurrence after radical prostatectomy.

Li F, Xu Y, Liu RL.

Int Urol Nephrol. 2019 Mar;51(3):443-451. doi: 10.1007/s11255-019-02096-3. Epub 2019 Feb 9.

PMID:
30739268
16.

Expression of KIF18A Is Associated with Increased Tumor Stage and Cell Proliferation in Prostate Cancer.

Zhang H, Shen T, Zhang Z, Li Y, Pan Z.

Med Sci Monit. 2019 Aug 27;25:6418-6428. doi: 10.12659/MSM.917352.

17.

Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression.

Kamdar S, Isserlin R, Van der Kwast T, Zlotta AR, Bader GD, Fleshner NE, Bapat B.

Clin Epigenetics. 2019 Mar 27;11(1):54. doi: 10.1186/s13148-019-0651-z.

18.

Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer.

Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE.

Oncogene. 2000 Mar 2;19(10):1288-96.

19.

Evidence of surfactant protein A and D expression decrement and their localizations in human prostate adenocarcinomas.

Kankavi O, Baykara M, Eren Karanis MI, Bassorgun CI, Ergin H, Ciftcioglu MA.

Ren Fail. 2014 Mar;36(2):258-65. doi: 10.3109/0886022X.2013.846831. Epub 2013 Oct 29.

PMID:
24168624
20.

SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System.

Pierconti F, Martini M, Cenci T, Petrone GL, Ricci R, Sacco E, Bassi PF, Larocca LM.

Prostate. 2017 May;77(6):597-603. doi: 10.1002/pros.23299. Epub 2017 Feb 1.

PMID:
28144985

Supplemental Content

Support Center